Eton Pharmaceuticals (ETON) risk factors, FY2024 10-K

Risks Relating to Our Business

1. 01We may need to grow the size of our organization, and we could experience difficulties in managing this growth
2. 02We focus on rare diseases, which may create additional risks and challenges, including that the target patient populations of our products and product candidates may be small
3. 03If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
4. 04a decline in the value of our stock
5. 05We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions
6. 06We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively
7. 07Use of artificial intelligence-based software by us or third parties with which we contract, may lead to the release of confidential information which may impact our ability to realize the benefits of our intellectual property
8. 08Sales of counterfeits of any of our product candidates, as well as unauthorized sales of any of our product candidates, may have adverse effects on our revenues, business and results of operations and damage our brand and reputation

Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization

1. 09We depend entirely on the success of current approved products and our new product candidates. If we are unable to generate revenues from our approved products and new product candidates, our ability to create stockholder value will be limited
2. 10We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively
3. 11We face substantial competition, which may result in others discovering, developing and commercializing products before or more successfully than our product candidates
4. 12Our competitors may obtain FDA or other regulatory approval for comparable products more rapidly than we may obtain approval for ours, and the risk of our competitors doing so may lead us to develop drug candidates without disclosing certain information with regard to such candidates
5. 13If we are not able to obtain any required regulatory approvals for our product candidates, we will not be able to commercialize our product candidate and our ability to generate revenue will be limited
6. 14the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval
7. 15An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval of our product candidate
8. 16Even if we receive regulatory approval for our additional product candidates, we may not be able to successfully commercialize these products, and the revenue that we generate from those sales, if any, may be limited
9. 17the willingness of patients to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement or government pricing approvals
10. 18The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product liability exposure
11. 19Significant additional labeling or warning requirements or limitations on the availability of our products may inhibit sales of affected products
12. 20Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain
13. 21If we market our existing approved products or any of our new product candidates in a manner that violates health care fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties
14. 22We may not be able to establish agreements with third parties with whom we wish to collaborate and, if we are able to establish them, we may not be able to establish them on commercially reasonable terms, which could result in alterations or delays of our development and commercialization plans
15. 23We enter into various contracts in the normal course of our business, some or all of which may require us to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have an adverse effect on our business, financial condition and results of operations
16. 24Any termination or suspension of, or delays in the commencement or completion of, any necessary studies of any of our product candidates for any indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects
17. 25government or regulatory delays or “clinical holds” requiring suspension or termination of a trial
18. 26Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results
19. 27We are subject to extensive laws and regulations related to data privacy, and our failure to comply with these laws and regulations could harm our business

Risks Relating to Our Intellectual Property Rights

1. 28We will depend on rights to certain pharmaceutical compounds that have been acquired by us. We do not have complete control over these pharmaceutical compounds and any loss of our rights to them could prevent us from selling our products
2. 29It may be difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights
3. 30We may not be able to protect our intellectual property rights throughout the world
4. 31If we fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability
5. 32Changes in either U.S. patent law or interpretation of such laws could diminish the value of patents in general, thereby impairing our ability to protect our products
6. 33Our product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts
7. 34require us to enter into royalty or licensing agreements
8. 35Others may claim an ownership interest in our intellectual property, which could expose us to litigation and have an adverse effect on our prospects
9. 36We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers

Risks Related to Owning Our Common Stock

1. 37We are currently unable to comply with the requirement to provide separate audited financial statements and unaudited pro forma financial information for the INCRELEX® product acquisition, specified by Item 9.01 of Form 8-K
2. 38could, depending on if and/or when the financial statements are created and become available and we file them, have other material and adverse consequences that are summarized below
3. 39An active, liquid and orderly trading market for our shares may not continue to be developed or sustained
4. 40Future capital raises may dilute our existing stockholders’ ownership, could depress the market price for our common stock and have other adverse effects on our operations
5. 41The trading price of the shares of our common stock may continue to be volatile, and purchasers of our common stock could incur substantial losses
6. 42general economic and market conditions and other factors, including factors unrelated to our operating performance
7. 43We are a “smaller reporting company” and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors
8. 44We have not paid dividends in the past and have no immediate plans to pay dividends, so any returns will be limited to the value of our stock
9. 45If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our shares, the price of our shares could decline
10. 46Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
11. 47Assuming a market for our common stock continues to develop, sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock price to fall
12. 48We may be at an increased risk of securities class action litigation
13. 49Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable
14. 50provide that all vacancies may be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum
15. 51any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, but excluding actions to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction
16. 52Ownership portions held by our executives and directors may limit our stockholders’ ability to influence corporate matters